Compare JFrog Ltd. Ordinary Shares (FROG) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JFrog Ltd. Ordinary Shares vs Hinge Health Inc. Class A Common Stock — how do they compare? JFrog Ltd. Ordinary Shares trades at $91.27 (market cap $12.24B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: JFrog Ltd. Ordinary Shares is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, JFrog Ltd. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JFrog Ltd. Ordinary Shares for 5 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FROG | HNGE | |
|---|---|---|
Market Cap | $12.24B | $8.48B |
Volume | 1,786,951 | 879,799 |
Sector | Technology | Health |
52-Week High | $104.03 | $105.14 |
52-Week Low | $34.75 | $31.17 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $11.43B | $8.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JFrog (FROG) trades at $99.28, up 0.26% on the day, showing strong technical momentum with a bullish moving average signal and trading near pivot point resistance at $99. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending, while maintaining robust revenue growth projections from $532M in 2025 to $600M in 2026. Recent product announcements at swampUP 2026 focused on AI-era software supply chain security enhancements.
Wall Street maintains strong bullish sentiment with 87.5% buy ratings and a $110.25 consensus price target, representing 11% upside potential. However, negative profitability metrics and insider selling activity present near-term headwinds. The stock's elevated P/S ratio of 19.77 requires continued execution on growth targets to justify valuation.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JFrog Ltd. Ordinary Shares
JFrog provides software supply chain tools that help developers manage, secure, and distribute software packages. Its platform is used across development and deployment workflows.
Read more on FROG →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
